NASDAQ:DWTX Dogwood Therapeutics (DWTX) Stock Price, News & Analysis $4.76 -0.10 (-2.06%) Closing price 08/6/2025 03:57 PM EasternExtended Trading$6.00 +1.24 (+26.05%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Dogwood Therapeutics Stock (NASDAQ:DWTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dogwood Therapeutics alerts:Sign Up Key Stats Today's Range$4.73▼$4.9050-Day Range$4.50▼$5.6052-Week Range$1.62▼$29.28Volume10,608 shsAverage Volume22,628 shsMarket Capitalization$9.09 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company Overview Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA. Read More Dogwood Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreDWTX MarketRank™: Dogwood Therapeutics scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingDogwood Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageDogwood Therapeutics has received no research coverage in the past 90 days.Read more about Dogwood Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Dogwood Therapeutics are expected to grow in the coming year, from ($6.43) to ($4.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dogwood Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dogwood Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Dogwood Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for DWTX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDogwood Therapeutics does not currently pay a dividend.Dividend GrowthDogwood Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for DWTX. News and Social Media1.1 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Dogwood Therapeutics this week, compared to 1 article on an average week.Search Interest1 people have searched for DWTX on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Dogwood Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dogwood Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.90% of the stock of Dogwood Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 9.05% of the stock of Dogwood Therapeutics is held by institutions.Read more about Dogwood Therapeutics' insider trading history. Receive DWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dogwood Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DWTX Stock News HeadlinesDogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025August 6 at 9:15 AM | globenewswire.comDogwood Therapeutics Approves CFO Salary IncreaseJuly 25, 2025 | theglobeandmail.comAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live. | The Oxford Club (Ad)Dogwood Therapeutics raises CFO Angela Walsh’s base salary to $321,903July 4, 2025 | investing.comDogwood Therapeutics Approves Equity Plan AmendmentJune 24, 2025 | tipranks.comDWTX Dogwood Therapeutics, Inc.June 10, 2025 | seekingalpha.comDogwood Therapeutics to Present at Sidoti Small-Cap Virtual ConferenceJune 3, 2025 | finance.yahoo.comDogwood Therapeutics to Present at Sidoti Small-Cap Virtual ConferenceJune 3, 2025 | globenewswire.comSee More Headlines DWTX Stock Analysis - Frequently Asked Questions How have DWTX shares performed this year? Dogwood Therapeutics' stock was trading at $2.49 on January 1st, 2025. Since then, DWTX stock has increased by 91.2% and is now trading at $4.76. How were Dogwood Therapeutics' earnings last quarter? Dogwood Therapeutics, Inc (NASDAQ:DWTX) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($4.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.77) by $3.44. When did Dogwood Therapeutics' stock split? Shares of Dogwood Therapeutics reverse split before market open on Wednesday, October 9th 2024.A 1-25 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Dogwood Therapeutics? Shares of DWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/08/2025Today8/07/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DWTX CIK1818844 Webwww.dwtx.com Phone(866) 620-8655FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Price Target for Dogwood Therapeutics$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+110.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($18.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.35 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-34.74% Debt Debt-to-Equity RatioN/A Current Ratio7.43 Quick Ratio7.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($7.56) per share Price / Book-0.63Miscellaneous Outstanding Shares1,910,000Free Float1,836,000Market Cap$9.09 million OptionableN/A Beta1.80 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:DWTX) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dogwood Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Dogwood Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.